| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Experimental Therapeutics, Preclinical Pharmacology |
Department of Molecular Oncology, Division of Medicine, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030 [A. M. E., T. S., M. M., G. B. M.], and Graduate School of Pharmaceutical Sciences, The University of Tokyo, Tokyo 113-0033, Japan [J. A.]
Ascitic fluid and plasma from ovarian cancer patients, but not from patients with nongynecological tumors, contain elevated levels of the bioactive phospholipid lysophosphatidic acid (LPA). We show that ovarian cancer cells constitutively produce increased amounts of LPA as compared with normal ovarian epithelium, the precursor of ovarian epithelial cancer, or breast cancer cells. In addition, LPA, but not other growth factors, increases LPA production by the OVCAR-3 ovarian cancer cell line but not by normal ovarian epithelium or breast cancer cell lines. We show that phospholipase D activity contributes to both constitutive and LPA-induced LPA production by ovarian cancer cells. Constitutive and LPA-induced LPA synthesis by ovarian cancer cells is differentially regulated with respect to the requirement of specific phospholipase A2 (PLA2) subgroups. Group IB (pancreatic) secretory PLA2 plays a critical role in both constitutive and LPA-induced LPA formation, whereas group IIA (synovial) secretory PLA2 contributes to LPA-induced LPA production only. Calcium-dependent and/or -independent cytosolic PLA2s are required for constitutive LPA synthesis but do not play a role in LPA-induced LPA formation. LPA increases the proliferation of ovarian cancer cells, decreases sensitivity to cisplatin, the most commonly used drug in ovarian cancer, decreases apoptosis and anoikis, increases protease production, and increases production of neovascularization mediators. Thus, an understanding of the source and regulation of LPA production in ovarian cancer patients could identify novel targets for therapy.
This article has been cited by other articles:
|
|
 |
|
  X. Ye Lysophospholipid signaling in the function and pathology of the reproductive system Hum. Reprod. Update, June 25, 2008; (2008) dmn023v2. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. S. Jeon, H. J. Moon, M. J. Lee, H. Y. Song, Y. M. Kim, M. Cho, D.-S. Suh, M.-S. Yoon, C. L. Chang, J. S. Jung, et al. Cancer-Derived Lysophosphatidic Acid Stimulates Differentiation of Human Mesenchymal Stem Cells to Myofibroblast-Like Cells Stem Cells, March 1, 2008; 26(3): 789 - 797. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. C. Chan, W. Peters, Y. Xu, J. Chun, R. V. Farese Jr, and S. Cases LPA3 receptor mediates chemotaxis of immature murine dendritic cells to unsaturated lysophosphatidic acid (LPA) J. Leukoc. Biol., November 1, 2007; 82(5): 1193 - 1200. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. M. Murph, J. Hurst-Kennedy, V. Newton, D. N. Brindley, and H. Radhakrishna Lysophosphatidic Acid Decreases the Nuclear Localization and Cellular Abundance of the p53 Tumor Suppressor in A549 Lung Carcinoma Cells Mol. Cancer Res., November 1, 2007; 5(11): 1201 - 1211. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T.-V. Do, J. C. Symowicz, D. M. Berman, L. A. Liotta, E. F. Petricoin III, M. S. Stack, and D. A. Fishman Lysophosphatidic Acid Down-Regulates Stress Fibers and Up-Regulates Pro-Matrix Metalloproteinase-2 Activation in Ovarian Cancer Cells Mol. Cancer Res., February 1, 2007; 5(2): 121 - 131. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F.-q. Wang, Y. Smicun, N. Calluzzo, and D. A. Fishman Inhibition of Matrilysin Expression by Antisense or RNA Interference Decreases Lysophosphatidic Acid-Induced Epithelial Ovarian Cancer Invasion Mol. Cancer Res., November 1, 2006; 4(11): 831 - 841. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K.-S. Kim, S. Sengupta, M. Berk, Y.-G. Kwak, P. F. Escobar, J. Belinson, S. C. Mok, and Y. Xu Hypoxia Enhances Lysophosphatidic Acid Responsiveness in Ovarian Cancer Cells and Lysophosphatidic Acid Induces Ovarian Tumor Metastasis In vivo Cancer Res., August 15, 2006; 66(16): 7983 - 7990. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Ren, Y.-j. Xiao, L. S. Singh, X. Zhao, Z. Zhao, L. Feng, T. M. Rose, G. D. Prestwich, and Y. Xu Lysophosphatidic Acid is constitutively produced by human peritoneal mesothelial cells and enhances adhesion, migration, and invasion of ovarian cancer cells. Cancer Res., March 15, 2006; 66(6): 3006 - 3014. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. A. Neidlinger, S. K. Larkin, A. Bhagat, G. P. Victorino, and F. A. Kuypers Hydrolysis of Phosphatidylserine-exposing Red Blood Cells by Secretory Phospholipase A2 Generates Lysophosphatidic Acid and Results in Vascular Dysfunction J. Biol. Chem., January 13, 2006; 281(2): 775 - 781. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Iorio, D. Mezzanzanica, P. Alberti, F. Spadaro, C. Ramoni, S. D'Ascenzo, D. Millimaggi, A. Pavan, V. Dolo, S. Canevari, et al. Alterations of Choline Phospholipid Metabolism in Ovarian Tumor Progression Cancer Res., October 15, 2005; 65(20): 9369 - 9376. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Li, X. Ye, C. Mahanivong, D. Bian, J. Chun, and S. Huang Signaling Mechanisms Responsible for Lysophosphatidic Acid-induced Urokinase Plasminogen Activator Expression in Ovarian Cancer Cells J. Biol. Chem., March 18, 2005; 280(11): 10564 - 10571. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Miyamoto, M. Hirata, A. Yamazaki, T. Kageyama, H. Hasuwa, H. Mizushima, Y. Tanaka, H. Yagi, K. Sonoda, M. Kai, et al. Heparin-Binding EGF-Like Growth Factor Is a Promising Target for Ovarian Cancer Therapy Cancer Res., August 15, 2004; 64(16): 5720 - 5727. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Bian, S. Su, C. Mahanivong, R. K. Cheng, Q. Han, Z. K. Pan, P. Sun, and S. Huang Lysophosphatidic Acid Stimulates Ovarian Cancer Cell Migration via a Ras-MEK Kinase 1 Pathway Cancer Res., June 15, 2004; 64(12): 4209 - 4217. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Hiramatsu, H. Sonoda, Y. Takanezawa, R. Morikawa, M. Ishida, K. Kasahara, Y. Sanai, R. Taguchi, J. Aoki, and H. Arai Biochemical and Molecular Characterization of Two Phosphatidic Acid-selective Phospholipase A1s, mPA-PLA1{alpha} and mPA-PLA1{beta} J. Biol. Chem., December 5, 2003; 278(49): 49438 - 49447. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Luquain, A. Singh, L. Wang, V. Natarajan, and A. J. Morris Role of phospholipase D in agonist-stimulated lysophosphatidic acid synthesis by ovarian cancer cells J. Lipid Res., October 1, 2003; 44(10): 1963 - 1975. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. L. Tanyi, Y. Hasegawa, R. Lapushin, A. J. Morris, J. K. Wolf, A. Berchuck, K. Lu, D. I. Smith, K. Kalli, L. C. Hartmann, et al. Role of Decreased Levels of Lipid Phosphate Phosphatase-1 in Accumulation of Lysophosphatidic Acid in Ovarian Cancer Clin. Cancer Res., September 1, 2003; 9(10): 3534 - 3545. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. L. Tanyi, A. J. Morris, J. K. Wolf, X. Fang, Y. Hasegawa, R. Lapushin, N. Auersperg, Y. J. Sigal, R. A. Newman, E. A. Felix, et al. The Human Lipid Phosphate Phosphatase-3 Decreases the Growth, Survival, and Tumorigenesis of Ovarian Cancer Cells: Validation of the Lysophosphatidic Acid Signaling Cascade as a Target for Therapy in Ovarian Cancer Cancer Res., March 1, 2003; 63(5): 1073 - 1082. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Aoki, A. Taira, Y. Takanezawa, Y. Kishi, K. Hama, T. Kishimoto, K. Mizuno, K. Saku, R. Taguchi, and H. Arai Serum Lysophosphatidic Acid Is Produced through Diverse Phospholipase Pathways J. Biol. Chem., December 6, 2002; 277(50): 48737 - 48744. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Sonoda, J. Aoki, T. Hiramatsu, M. Ishida, K. Bandoh, Y. Nagai, R. Taguchi, K. Inoue, and H. Arai A Novel Phosphatidic Acid-selective Phospholipase A1 That Produces Lysophosphatidic Acid J. Biol. Chem., September 6, 2002; 277(37): 34254 - 34263. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. M. Baudhuin, K. L. Cristina, J. Lu, and Y. Xu Akt Activation Induced by Lysophosphatidic Acid and Sphingosine-1-phosphate Requires Both Mitogen-Activated Protein Kinase Kinase and p38 Mitogen-Activated Protein Kinase and Is Cell-Line Specific Mol. Pharmacol., September 1, 2002; 62(3): 660 - 671. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. T. Budnik and A. K. Mukhopadhyay Lysophosphatidic Acid and Its Role in Reproduction Biol Reprod, April 1, 2002; 66(4): 859 - 865. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Tigyi Selective Ligands for Lysophosphatidic Acid Receptor Subtypes: Gaining Control over the Endothelial Differentiation Gene Family Mol. Pharmacol., December 1, 2001; 60(6): 1161 - 1164. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Cell Growth & Differentiation |
